Key result
Both fenofibrate and atorvastatin significantly improved peak blood flow from baseline (to 536 ml/min and 570 ml/min, respectively), with no significant difference between treatments (P=0.47).
Why the study?
Does fenofibrate compared to atorvastatin improve endothelium-dependent vascular reactivity in males with combined hyperlipidaemia?
RCT (n=29)
single-blind
randomized
Does fenofibrate compared to atorvastatin improve endothelium-dependent vascular reactivity in males with combined hyperlipidaemia?
Absolute Event Rate: 536% vs 570%
p-value: p=0.47
Both fenofibrate and atorvastatin significantly improve endothelium-dependent vascular reactivity in men with combined hyperlipidaemia, with comparable efficacy.
No takes yet. Share an insight, caveat, or question.
Either drug may be selected for vascular benefits in combined hyperlipidaemia; confirms comparable endothelial effects in this RCT.
Jan Malík (2001) conducted an RCT in combined hyperlipidaemia (n=29). Fenofibrate vs. Atorvastatin 10 mg daily was evaluated on Peak blood flow (PBF) (p=0.47). Both fenofibrate and atorvastatin significantly improved peak blood flow from baseline (to 536 ml/min and 570 ml/min, respectively), with no significant difference between treatments (P=0.47).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: